Capricor (CAPR) Securities Investigation Notice - Levi & Korsinsky

CAPR shareholders saw a 60% to 70% drop after FDA briefing documents identified significant concerns regarding Deramiocel's efficacy and regulatory prospects. The investigation focuses on whether Capricor adequately disclosed material risks related to the FDA review process and...